Cardiovascular Systems (CSII) Given News Impact Score of 0.11
News articles about Cardiovascular Systems (NASDAQ:CSII) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiovascular Systems earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 45.8079467854758 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- BidaskClub Lowers Cardiovascular Systems (CSII) to Strong Sell (americanbankingnews.com)
- Reviewing K2M Group (KTWO) and Cardiovascular Systems (CSII) (americanbankingnews.com)
- Cardiovascular Systems Inc (CSII) Forecasted to Post FY2018 Earnings of $0.02 Per Share (americanbankingnews.com)
- Analysts Anticipate Cardiovascular Systems Inc (CSII) Will Post Earnings of -$0.04 Per Share (americanbankingnews.com)
- Cardiovascular Systems (CSII) Earns Hold Rating from Analysts at William Blair (americanbankingnews.com)
A number of equities research analysts have weighed in on CSII shares. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target (down from $37.00) on shares of Cardiovascular Systems in a report on Thursday, October 26th. Raymond James Financial reissued a “hold” rating on shares of Cardiovascular Systems in a report on Monday, December 4th. Zacks Investment Research raised shares of Cardiovascular Systems from a “sell” rating to a “hold” rating in a report on Monday, November 13th. William Blair reissued a “market perform” rating on shares of Cardiovascular Systems in a report on Thursday, December 21st. Finally, Citigroup started coverage on shares of Cardiovascular Systems in a report on Thursday, September 21st. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Cardiovascular Systems has a consensus rating of “Hold” and an average price target of $31.50.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Wednesday, October 25th. The medical device company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The company had revenue of $49.70 million during the quarter, compared to analyst estimates of $51.00 million. During the same period in the prior year, the firm earned ($0.06) earnings per share. The business’s quarterly revenue was down .2% on a year-over-year basis. equities research analysts predict that Cardiovascular Systems will post -0.03 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2017/12/28/cardiovascular-systems-csii-given-news-impact-score-of-0-11.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.